EV101
Metastatic Colorectal Cancer (Microsatellite Stable subtype)
Pre-clinicalActive
Key Facts
Indication
Metastatic Colorectal Cancer (Microsatellite Stable subtype)
Phase
Pre-clinical
Status
Active
Company
About EV Therapeutics
EV Therapeutics is a San Diego-based biotech startup founded in 2018, pioneering a novel extracellular vesicle (EV) platform for cancer immunotherapy. The company's core technology involves engineering tumor-derived EVs to deliver immune-stimulating neoantigens while removing immunosuppressive factors, aiming to convert 'cold' tumors responsive to treatment, especially in combination with checkpoint blockade. Initially targeting the high-unmet-need metastatic colorectal cancer market, where most patients have microsatellite stable (MSS) tumors resistant to current immunotherapies, the company is in pre-clinical development with its lead candidate EV101.
View full company profile